| AFC-HD AMS Life Science Co. Ltd. (2927.TO) | ||
| Japan | ||
| Half-Year Ended February 28 | ||
| GROUP | 2025 | 2024 |
| Revenue | Y16.61 bln | Y14.54 bln |
| Operating Profit | Y1.29 bln | Y1.02 bln |
| Pretax Profit | Y1.33 bln | Y1.06 bln |
| Net Profit | Y881.00 mln | Y641.00 mln |
| Per share | ||
| Earnings | Y62.65 | Y45.79 |
| Diluted Earnings | Y62.64 | Y45.74 |
| Results are based on Japanese accounting standards. |
(END) Dow Jones Newswires
| AFC-HD AMS Life Science Co. Ltd. also released the following forecasts: | |
| GROUP | Year Ending |
| Aug 2025 | |
| Revenue | Y31.10 bln |
| Operating Profit | Y2.20 bln |
| Pretax Profit | Y2.20 bln |
| Net Profit | Y1.32 bln |
| Per share | |
| Earnings | Y93.78 |
| Results are based on Japanese accounting standards. |
This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.
(END) Dow Jones Newswires
April 14, 2025 02:36 ET (06:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.